Get Started

OCGN

NASD Ocugen Inc
Nov 4, 2026 · 8:36 AM ET LAST TRADE Market Closed

$0.7901 ↑ +0.0449 (+6.03%) Trading Up from the previous close of $0.7452

YTD change
-41.47%
vs 20-day SMA
-3.08%
vs 200-day SMA
-44.32%

Price ranges

Previous day
$0.7317 $0.7899
open $0.7450 close $0.7452
+$0.0002 (+0.03%)
Today
$0.0000 $0.0000
$0.7901
Past week
$0.6909 $0.8037
from $0.7574 now $0.7901
+$0.0327 (+4.32%)
Past month
$0.6909 $1.0500
from $1.0400 now $0.7901
-$0.2499 (-24.03%)
This year
$0.6909 $2.7250
from $1.3500 now $0.7901
-$0.5599 (-41.47%)

Price & Performance

-1.10 (-59.72%) / 6M

$0.6109$1.05$1.50$1.94May 4Aug 4Nov 3

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 95.8% away from all-time highs of $18.7700
  • OCGN is down 41% since the beginning of the year
  • OCGN is down 45% over the past 12 months
  • OCGN is down 24% over the past 1 month
  • 32% of all OCGN investors are betting against OCGN

OCGN reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is -47.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.07
Earnings momentum -16.7% Quarterly EPS growth
Quarterly change -16.7%

Valuation

P/E ratio N/A
Enterprise value $240.3M
Beta 2.13

Balance sheet & scale

IncomeN/A
Revenue$4.6M
Cash$100.1M
Debt$88.0K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $267.9M

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $461.26 -0.90%
MRNA Moderna, Inc. $228.44 +3.45%
RVMD Revolution Medicines, Inc. $194.23 +3.22%
ROIV Roivant Sciences Ltd. $36.04 +0.42%
BNTX BioNTech SE Sponsored ADR $86.92 -0.70%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.